Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Merck & Co Inc Triggers Response In 24% Of Lung Cancer Patients-Reuters


Tuesday, 1 Oct 2013 05:29pm EDT 

Reuters reported that Early data from a small trial of Merck & Co Inc experimental immunotherapy cancer drug, known as MK-3475, showed that about a quarter of lung cancer patients responded to the treatment. Data from the trial is slated for presentation in Sydney, Australia, later this month at the World Conference on Lung Cancer, Merck said in a statement. Merck said results from 38 patients whose cancer had stopped responding to earlier rounds of treatment showed that 24% had an immune-system response to the drug. The trial also showed that 21% of patients experienced tumor shrinkage. 

Company Quote

59.75
 --
26 Nov 2014